Lacking Shareholder Support, STAAR Surgical Terminates Alcon Merger Agreement

GENEVA and LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced that based on preliminary estimates by STAAR’s proxy solicitor, the company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at its special meeting of stockholders on Tuesday. As a result, STAAR has terminated its merger agreement with Alcon, per its Form 8-K filing with the U.S. Securities and Exchange Commission (SEC) late yesterday afternoon. No termination fee will be payable by either party, according to the announcement, and STAAR will remain a stand-alone, publicly traded company.